ANIX Director Purchases 10,000 Shares at $3.08 – Insider Buying Signal

Form 4 filing for Anixa Biosciences (ANIX): Company director Lewis H. Titterton, Jr. bought 10,000 common shares on 07/31/2025 at $3.08 per share, an outlay of roughly $30.8 k.

Rhea-AI Filing Summary

Form 4 filing for Anixa Biosciences (ANIX): Company director Lewis H. Titterton, Jr. bought 10,000 common shares on 07/31/2025 at $3.08 per share, an outlay of roughly $30.8 k.

The purchase lifts his direct holding to 953,334 shares. No sales or derivative transactions were disclosed. Because directors are presumed to possess intimate knowledge of corporate prospects, open-market buying is generally interpreted as a positive signal of confidence rather than a routine option exercise.

Positive

• Director insider purchase: 10,000 shares at $3.08 demonstrates incremental confidence and tighter shareholder alignment.

Negative

• None.

Insights

Financial Analyst

TL;DR: Director adds 10k ANIX shares; modest but positive insider signal.

The filing shows a straightforward open-market buy by Director Titterton. Although 10,000 shares is small relative to his nearly 1 m-share stake, it involves fresh cash at market prices and increases alignment with shareholders. No offsetting sales or derivative hedges appear, reinforcing the constructive signal. Impact is limited by the transaction’s size but still incrementally bullish for sentiment.

Insider Trade Summary

Net Buyer: 10,000 shares

Net Buy 1 txn

Insider Titterton Lewis H jr

Role Director

Bought 10,000 shs ($31K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	10,000	$3.08	$31K

Holdings After Transaction: Common Stock — 953,334 shares (Direct)

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When did the ANIX insider transaction occur?

The purchase was executed on July 31, 2025.

How many Anixa Biosciences shares were bought?

Director Lewis H. Titterton, Jr. acquired 10,000 common shares.

What price did the insider pay for ANIX shares?

The shares were purchased at $3.08 each.

What is the director’s total ANIX ownership after the trade?

Post-transaction, Titterton directly owns 953,334 shares.

Were any derivative securities involved?

No; the Form 4 shows no derivative transactions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 08/04/2025 - 09:00 AM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Titterton Lewis H jr

(Last) (First) (Middle)

C/O ANIXA BIOSCIENCES, INC.

3150 ALMADEN EXPRESSWAY, SUITE 250

(Street)

SAN JOSE, CA 95118

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Anixa Biosciences Inc [ ANIX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
07/31/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/31/2025		P		10,000	A	$3.08	953,334	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Lewis H. Titterton, Jr.	08/04/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.